摘要
背景:多发性骨髓瘤(MM)是以骨髓内浆细胞的增殖为特征的克隆性B细胞恶性肿瘤,仍是一种无法治愈的疾病,因此,迫切需要寻找新的治疗靶点。虽然microRNA-137 (miR-137)(参与多种细胞过程)已被报道在许多类型的肿瘤中低水平表达,其在MM中的作用仍不知道。 方法:在这项研究中,研究了在MM的miR-137靶基因和潜在的影响。 结果:结果显示MM患者的MM细胞株和CD138 +骨髓单个核细胞中miR-137表达明显下调的。双荧光素酶报告基因分析显示,MITF是miR-137直接目标。miR-137的超表达或MITF-shRNA的转染对丝氨酸/苏氨酸蛋白激酶(Akt)表达无显著影响,但MITF、c-Met、p-Akt蛋白的表达及其磷酸化底物蛋白明显下降,同时伴随着p53表达增加。此外,miR-137或MITF-shRNA的超表达显著提高了用地塞米松处理过的多发性骨髓瘤细胞36小时抑制率和凋亡率。MITF表达增加可能抵消在多发性骨髓瘤细胞中miR-137的生物学效应。 结论:我们的结论是MITF是miR-137的直接目标。miR-137可以通过降低受体的表达,进一步以MITF为目标降低Akt磷酸化提高多发性骨髓瘤细胞的激素敏感性。
关键词: AKT,c-Met,地塞米松敏感,miR-137,MITF,多发性骨髓瘤,磷酸化
图形摘要
Current Cancer Drug Targets
Title:miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF
Volume: 16 Issue: 9
Author(s): Benping Zhang, Ling Ma, Jia Wei, Jingyu Hu, Zichu Zhao, Youping Wang, Yan Chen, Fei Zhao
Affiliation:
关键词: AKT,c-Met,地塞米松敏感,miR-137,MITF,多发性骨髓瘤,磷酸化
摘要: Background: Multiple myeloma (MM), a clonal B cell malignancy characterized by the proliferation of plasma cells within the bone marrow, is still an incurable disease, and therefore, finding new therapeutic targets is urgently required. Although microRNA-137 (miR-137), which is involved in a variety of cellular processes, has been reported to be under-expressed in many types of solid tumors, its role in MM is less known.
Methods: In this study, the target gene and the potential effect of miR-137 in MM were investigated.
Results: The results showed significantly down regulated expression of miR-137 in MM cell lines and in the CD138+ bone marrow mononuclear cells of MM patients. A dual luciferase reporter gene analysis revealed that MITF is a direct target of miR-137. The overexpression of miR-137 or transfection of MITF-shRNA had no significant effect on the expression of serine/ threonine protein kinase (AKT), but the expression of MITF, c-MET, p-AKT, and its phosphorylated substrate protein decreased significantly, which was accompanied by an increase in p53 expression. In addition, the overexpression of miR-137 or MITF-shRNA significantly improved the 36-hour inhibition rate and apoptosis rate in multiple myeloma cells treated with dexamethasone. The overexpression of MITF could counteract the biological effect of miR-137 in multiple myeloma cells.
Conclusion: We conclude that MITF is a direct target of miR-137. The miR-137 can improve the dexamethasone sensitivity in multiple myeloma cells by reducing the c-MET expression and further decreasing the AKT phosphorylation via targeting MITF.
Export Options
About this article
Cite this article as:
Benping Zhang, Ling Ma, Jia Wei, Jingyu Hu, Zichu Zhao, Youping Wang, Yan Chen, Fei Zhao , miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/1568009616666160203114140
DOI https://dx.doi.org/10.2174/1568009616666160203114140 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections:
Recent Patents and Topics on Imaging (Discontinued) Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma
Combinatorial Chemistry & High Throughput Screening Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Infrequent Infections in COPD
Current Respiratory Medicine Reviews Zinc Complexes Developed as Metallopharmaceutics for Treating Diabetes Mellitus based on the Bio-Medicinal Inorganic Chemistry
Current Topics in Medicinal Chemistry B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer
Anti-Cancer Agents in Medicinal Chemistry Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse
Anti-Cancer Agents in Medicinal Chemistry Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Anticancer Drug Discovery Targeting DNA Hypermethylation
Current Medicinal Chemistry Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism High-level Soluble Expression, Purification, and Functional Characterization of the Recombinant Human Leukemia Inhibitory Factor: A Potential General Strategy for the Recombinant Expression of Cytokines Consisting of Four α-Helices in a Bundle
Protein & Peptide Letters Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
Current Pharmaceutical Design